InvestorsHub Logo
Followers 0
Posts 55
Boards Moderated 0
Alias Born 05/27/2017

Re: None

Tuesday, 10/10/2017 10:06:44 PM

Tuesday, October 10, 2017 10:06:44 PM

Post# of 15662
$HEB * Hemispherx Biopharma-? Ampligen appears to be generally well-tolerated by pancreatic patients in program, top line data expected to be reported before year-end?

* Hemispherx Biopharma-laying plans for cancer trials of Ampligen in U.S.; working on plans to expand early access to Ampligen to other european countries Source text for Eikon: Further company coverage: